IL–2 and IL-10 mRNA, B7-H1 expression, and B7-H1–specific mRNA in 24 HIV-infected patients undergoing highly active antiretroviral therapy (HAART) and in 12 HIV-infected, HAART-untreated patients
| . | HAART treated . | HAART untreated . | P . |
|---|---|---|---|
| Unstimulated PBMCs | |||
| IL-2 mRNA | 0.53 ± 0.31 | 0.88 ± 0.29 | NS |
| IL-10 mRNA | 3.06 ± 1.02 | 5.59 ± 0.97 | NS |
| B7-H1 expression on | |||
| CD3+cells | 5.34 ± 1.44 | 8.98 ± 2.51 | NS |
| CD14+cells | 19.37 ± 4.88 | 33.71 ± 8.55 | .043 |
| CD19+cells | 26.74 ± 4.58 | 39.91 ± 7.15 | .032 |
| B7-H1–specific mRNA | 19.04 ± 4.17 | 31.14 ± 5.88 | .033 |
| Stimulated PBMCs | |||
| IL-2 mRNA | 2.06 ± 0.87 | 3.18 ± 0.99 | NS |
| IL-10 mRNA | 3.62 ± 0.95 | 6.72 ± 1.12 | .017 |
| PDL-1 expression on | |||
| CD3+cells | 9.98 ± 2.54 | 14.17 ± 3.21 | NS |
| CD14+cells | 27.44 ± 4.19 | 39.81 ± 5.72 | .039 |
| CD19+cells | 37.81 ± 4.77 | 46.11 ± 6.22 | NS |
| B7-H1–specific mRNA | 78.12 ± 9.15 | 107.74 ± 14.32 | .041 |
| . | HAART treated . | HAART untreated . | P . |
|---|---|---|---|
| Unstimulated PBMCs | |||
| IL-2 mRNA | 0.53 ± 0.31 | 0.88 ± 0.29 | NS |
| IL-10 mRNA | 3.06 ± 1.02 | 5.59 ± 0.97 | NS |
| B7-H1 expression on | |||
| CD3+cells | 5.34 ± 1.44 | 8.98 ± 2.51 | NS |
| CD14+cells | 19.37 ± 4.88 | 33.71 ± 8.55 | .043 |
| CD19+cells | 26.74 ± 4.58 | 39.91 ± 7.15 | .032 |
| B7-H1–specific mRNA | 19.04 ± 4.17 | 31.14 ± 5.88 | .033 |
| Stimulated PBMCs | |||
| IL-2 mRNA | 2.06 ± 0.87 | 3.18 ± 0.99 | NS |
| IL-10 mRNA | 3.62 ± 0.95 | 6.72 ± 1.12 | .017 |
| PDL-1 expression on | |||
| CD3+cells | 9.98 ± 2.54 | 14.17 ± 3.21 | NS |
| CD14+cells | 27.44 ± 4.19 | 39.81 ± 5.72 | .039 |
| CD19+cells | 37.81 ± 4.77 | 46.11 ± 6.22 | NS |
| B7-H1–specific mRNA | 78.12 ± 9.15 | 107.74 ± 14.32 | .041 |
Mean ± SE and statistical significance are shown.